RHOA and metabolic dysfunction-associated steatotic liver disease: In the liver, α8β1 promotes fibrosis in NAFLD through RHOA signaling and upregulation of fibrotic markers, while modulation via miR-125b-5p demonstrates its therapeutic potential.